This article was originally published in The Gray Sheet
Firm is seeking an exclusive marketing and distribution partner for its DRx quantitative hCG patient monitor, for which FDA market go-ahead was announced Oct. 6. The single-use device measures levels of human chorionic gonadotropin (hCG) hormone in whole blood and is designed for use as an aid in monitoring pregnancy status. The test can be performed in a physician's office and provides results in less than ten minutes, according to the company
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.